On October 10, 2025, Karyopharm Therapeutics Inc. completed financing transactions, raising $12.5 million in borrowing, $15 million in 2028 convertible notes, and $103.5 million in 2029 convertible notes, impacting its financial strategy significantly. The company has 15,926,939 shares of common stock outstanding as of October 14, 2025.